Featured Research

from universities, journals, and other organizations

Older and younger chronic leukemia patients may need different therapy

Date:
December 12, 2012
Source:
Ohio State University Medical Center
Summary:
Age is usually not considered when determining treatment for people with chronic lymphocytic leukemia (CLL), but a new study indicates that older patients with CLL may require different therapy than younger patients. The findings highlight the importance of enrolling older patients on CLL trials and of developing trials that specifically target older patients.

Doctors should use different therapies when treating older and younger patients with chronic lymphocytic leukemia, according to a new study led by researchers at the Ohio State University Comprehensive Cancer Center -- Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC -- James).

Age is usually not considered when determining treatment for people with CLL, but this study indicates that older people with CLL may not respond as well to the therapy used for most patients.

The study was published Dec. 10 in the Journal of Clinical Oncology.

"Our analysis shows that optimal therapy for younger and older patients with chronic lymphocytic leukemia is likely to be different, at least when using current treatments," says first author Dr. Jennifer Woyach, assistant professor of hematology at the OSUCCC -- James.

"We hope this study will shape future research by highlighting the importance of enrolling older patients on clinical trials and of developing trials that specifically target older patients."

Doctors diagnose about 15,000 new cases of chronic lymphocytic leukemia (CLL) annually in the United States, making it the most common form of leukemia. It remains incurable, and about 4,400 Americans die of the malignancy each year. CLL most often occurs in people older than age 65; the average age at diagnosis is 72. Yet, most CLL clinical-trial participants are in their early 60s.

"Our findings apply to both routine care of CLL patients 70 years and older and to future CLL trials," says principal investigator Dr. John Byrd, a CLL specialist and professor of medicine, of medicinal chemistry and of veterinary biosciences at the OSUCCC -- James.

"The study suggests that chlorambucil is superior to fludarabine in older patients, and that CD20 antibody therapies such as rituximab are beneficial as front-line therapy for all CLL patients, regardless of age," says Byrd, who is the D. Warren Brown Designated Chair in Leukemia Research.

"These data also show that future treatment trials for older adults with CLL should build on CD20 antibody therapies such as rituximab and ofatumumab, but not on fludarabine or alemtuzumab."

Byrd, Woyach and their colleagues reviewed 663 CLL patients who were enrolled in four sequential CLL clinical trials evaluating front-line therapies. The researchers looked for differences in treatment outcomes between older and younger patients to identify the most effective therapy for older adults.

The four trials, all sponsored by the Cancer and Leukemia Group B (CALGB) clinical cooperative group, compared these treatments: chlorambucil versus fludarabine, fludarabine plus rituximab versus fludarabine, fludarabine with consolidation alemtuzumab, and fludarabine plus rituximab with consolidation alemtuzumab.

Key conclusions include:

  • Fludarabine versus chlorambucil: Fludarabine improved progression-free survival and overall survival among patients younger than age 70 but chlorambucil tended to produce higher overall survival in patients older than 70.
  • Rituximab combined with fludarabine, versus fludarabine alone, improves progression-free and overall survival in both younger and older patients.
  • Alemtuzumab consolidation therapy after chemotherapy or chemoimmunotherapy does not improve progression-free or overall survival in either younger or older patients.

Funding from the NIH/National Cancer Institute (grants CA31946, CA33601 and CA140158), the Leukemia and Lymphoma Society, the Harry Mangurian Foundation and the D. Warren Brown Family Foundation supported this research.

Other researchers involved in this study were Amy S. Ruppert and Susan Geyer of Ohio State; Kanti Rai and Jonathan Kolitz of North Shore-Long Island Jewish Medical System; Martin S. Tallman, Memorial Sloan-Kettering Cancer Center; Thomas S. Lin, GlaxoSmithKline; Frederick R. Appelbaum, Fred Hutchinson Cancer Research Center; Andrew R. Belch, Cross Cancer Institute, Edmonton, Alberta, Canada; Vicki A. Morrison, University of Minnesota and Veterans Affairs Medical Center; and Richard A. Larson, University of Chicago.


Story Source:

The above story is based on materials provided by Ohio State University Medical Center. Note: Materials may be edited for content and length.


Journal Reference:

  1. J. A. Woyach, A. S. Ruppert, K. Rai, T. S. Lin, S. Geyer, J. Kolitz, F. R. Appelbaum, M. S. Tallman, A. R. Belch, V. A. Morrison, R. A. Larson, J. C. Byrd. Impact of Age on Outcomes After Initial Therapy With Chemotherapy and Different Chemoimmunotherapy Regimens in Patients With Chronic Lymphocytic Leukemia: Results of Sequential Cancer and Leukemia Group B Studies. Journal of Clinical Oncology, 2012; DOI: 10.1200/JCO.2011.41.5646

Cite This Page:

Ohio State University Medical Center. "Older and younger chronic leukemia patients may need different therapy." ScienceDaily. ScienceDaily, 12 December 2012. <www.sciencedaily.com/releases/2012/12/121212130852.htm>.
Ohio State University Medical Center. (2012, December 12). Older and younger chronic leukemia patients may need different therapy. ScienceDaily. Retrieved July 29, 2014 from www.sciencedaily.com/releases/2012/12/121212130852.htm
Ohio State University Medical Center. "Older and younger chronic leukemia patients may need different therapy." ScienceDaily. www.sciencedaily.com/releases/2012/12/121212130852.htm (accessed July 29, 2014).

Share This




More Health & Medicine News

Tuesday, July 29, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Generics Eat Into Pfizer's Sales

Generics Eat Into Pfizer's Sales

Reuters - Business Video Online (July 29, 2014) Pfizer, the world's largest drug maker, cut full-year revenue forecasts because generics could cut into sales of its anti-arthritis drug, Celebrex. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
Nigeria Ups Ebola Stakes on 1st Death

Nigeria Ups Ebola Stakes on 1st Death

Reuters - Business Video Online (July 29, 2014) Nigerian authorities have shut and quarantined a Lagos hospital where a Liberian man died of the Ebola virus, the first recorded case of the highly-infectious disease in Africa's most populous economy. David Pollard reports Video provided by Reuters
Powered by NewsLook.com
Running 5 Minutes A Day Might Add Years To Your Life

Running 5 Minutes A Day Might Add Years To Your Life

Newsy (July 29, 2014) According to a new study, just five minutes of running or jogging a day could add years to your life. Video provided by Newsy
Powered by NewsLook.com
Ebola Outbreak Poses Little Threat To U.S.: CDC

Ebola Outbreak Poses Little Threat To U.S.: CDC

Newsy (July 29, 2014) The Ebola outbreak in West Africa poses little threat to Americans, according to officials with the Centers for Disease Control and Prevention. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins